comparemela.com

Latest Breaking News On - Darren opland - Page 14 : comparemela.com

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received

Italy
Japan
United-states
Paris
France-general
France
French
Italian
Japanese
American
Alexandre-lebeaut
Guillaume-van-renterghem-lifesci

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins. CoVepiT, based on 13 peptides, elicits durable T-cell

Italy
France
French
Italian
Dominique-costantini
Guillaume-van-renterghem-lifesci
Thomas-guillot
Florence-portejoie
Darren-opland
Nantes-university-hospital
Linkedin
Lifesci-communications

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

At American Association for Cancer Research Annual Meeting 2022 New Orleans, April 8 13 Regulatory News: OSE Immunotherapeutics (Paris:OSE)(ISIN: FR0012127173; Mnemo: OSE), today announced that

Italy
Louisiana
United-states
New-orleans
France
New-orleans-convention-center
French
Italian
American
Guillaume-van-renterghem-lifesci
Thomas-guillot
Florence-portejoie

OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company . Alexandre

Italy
Maryland
United-states
Paris
France-general
France
French
Italian
American
Alexandre-lebeaut
Guillaume-van-renterghem-lifesci
Thomas-guillot

OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained fast track designation

Paris
France-general
France
Italy
United-states
French
Italian
Ulf-meier-kriesche
Asahi-kasei
Guillaume-van-renterghem-lifesci
Thomas-guillot
Mark-hensley

vimarsana © 2020. All Rights Reserved.